NCT05735392 - Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer (GIM21 Trial) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 7, 2018

Primary Completion Date

January 12, 2022

Study Completion Date

January 12, 2022

Conditions

Metastatic Breast Cancer

Interventions

OTHER

Both blood and tissues collection for patients with metastatic breast cancer HER2+ pretreated with no more than one line of anti-HER2 therapy for advanced breast cancer.

Both blood and tissues will be obtained duringT-DM1 treatment of enrolled patients at the participating Sites at the study specific timelines.

Trial Locations (9)

Unknown

A.O. Ospedale Papa Giovanni XXIII - Oncologia, Bergamo

I.R.C.C.S. A.O.U San Martino - IST, Genova

A.O.U. Policlinico di Modena, Modena

Azienda Ospedaliera Universitaria Federico II, Napoli

Ospedale S. Cuore Don Calabria, Negrar

Fondazione Policlinico Universitario A. Gemelli - Oncologia Medica, Roma

Fondazione Policlinico Universitario A. Gemelli - Senologia Oncologica, Roma

"Istituto Nazionale Tumori Regina Elena", Roma

Policlinico Umberto I, Rome

All Listed Sponsors

lead

Consorzio Oncotech

OTHER